Spravato/Esketamine
A Different Approach to Treatment
At Complete Mind Can of PA we are dedicated to providing our patients with alternative treatment options, not just for better outcomes to sooner symptom alleviation. Spravato® provides our patients with an opportunity for fast acting relief, with the possibility to start feeling better quickly.
Fast action During clinical studies, Spravato® lessened depression symptoms within hours after it was taken. This is unlike many other depression medications, which can take weeks to start working.
What Can We Treat?
Treatment-resistant depression (TRD)
Treatment-resistant depression (TRD) is depression that hasn’t improved after treatment with two or more anti-depressants.
Major Depressive Disorder (MDD)
Major depressive disorder (MDD) with thoughts or actions of suicide However, if you are having active suicidal thoughts, it is recommended that you seek emergency help right away.
How Does It Work?
“Esketamine, the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. In other words, it is an NMDA-receptor antagonist. The mechanism by which esketamine exerts its antidepressant effect is unknown.” According to the FDA, “Spravato nasal spray demonstrated statistically significant effect compared to placebo on the severity of depression, and some effect was seen within two days.”
What is The Dosing for Spravato?
Day 1 starting dose: 56mg
Subsequent doses: 56mg or 84mg
Administer once weekly
56mg or 84mg
56mg or 84mg
*Dosing frequency should be individualized to the least frequent dosing to maintain remission/response.
Should a Patient With High Blood Pressure Take Spravato®?
Spravato® can increase a patient’s blood pressure temporarily – for about four hours – so patients will have their blood pressure measured at various times, including before and after taking Spravato®
If patient’s blood pressure is high before using this medicine, a patient’s healthcare provider will decide whether to start the medicine or wait until their blood pressure is lower.
Patients should not take Spravato® if they have a blood vessel disease (aneurysm), an abnormal connection between their blood vessels (arteriovenous malformation) or a history of bleeding in the brain.
Patients should tell their Spravato® provider right away if they get chest pain, shortness of breath, sudden severe headache, change in vision or seizures after taking Spravato®.
